The regulatory environment for the life sciences industry is undergoing fundamental changes in Europe. These changes are far-reaching and will have significant impacts which will be felt at all levels for the next decade or more. Richard Young of Sensus Group explores some of these impacts in the areas of resources, cross-sector impacts and cost/innovation and suggests possible strategies which may need to be examined for the industry’s future.
[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2018/10/Regulatory-convergence-in-European.pdf” width=”100%” height=”900px” style=”border:0;”]
